| ¿µ¹® | neurotransmitter | ÇÑ±Û | ½Å°æÀü´Þ¹°Áú |
|---|---|---|---|
| ¼³¸í | ü³»ÀÇ ½Å°æ ¼¼Æ÷¿¡¼ ¹æÃâµÇ¸ç ÀÎÁ¢ÇÏ´Â ½Å°æ¼¼Æ÷³ª ±ÙÀ°¿¡ Á¤º¸¸¦ Àü´ÞÇÏ´Â ¹°Áú. ½Å°æ¼¼Æ÷³»¿¡¼ ÇÕ¼ºµÇ¾î¼ ½Å°æÁ¾¸»ÀÇ ¿¬Á¢¼ÒÆ÷¿¡ ÀúÀåµÈ´Ù. Àڱؿ¡ ÀÇÇØ¼ ¿¬Á¢°£±Ø¿¡ À¯¸®µÇ¾î¼ ¼ö¿ëü¿Í °áÇÕÇÏ¿© Á¤º¸¸¦ ´ÙÀ½ ¼¼Æ÷·Î ÀüÇÑ´Ù. Àü±âÀûÀ¸·Î°¡ ¾Æ´Ï¶ó ÈÇй°Áú¿¡ ÀÇÇØ¼ ¿¬Á¢°£±ØÀ» °ÅÃÄ Á¤º¸¸¦ ÀüÇϱ⠶§¹®¿¡ ÈÇÐÀü´Þ¹°ÁúÀ̶ó°íµµ ÇÑ´Ù. ¿¬Á¢Èĸ·(°æ¿ì¿¡ µû¶ó¼ ¿¬Á¢Àü¸·)À» ÈïºÐ(Å»ºÐ±Ø)½ÃŰ´Â ÈïºÐ¼ºÀü´Þ¹°Áú°ú ¾ïÁ¦(°úºÐ±Ø)ÇÏ´Â ¾ïÁ¦¼º Àü´Þ¹°ÁúÀÌ ÀÖ´Ù. ¾Æ¼¼Æ¿Äݸ°, ³ë¸£¿¡Çdz×ÇÁ, µµÆÄ¹Î, ±Û¸®½Å, ¥ã-¾Æ¹Ì³ëºäÄ¥»ê(GABA)µî °°Àº ½Å°æÀü´Þ¹°ÁúÀÌ¶óµµ ¼ö¿ëü¿¡ µû¶ó¼ ÈïºÐ¼º°ú ¾ïÁ¦¼ºÀ¸·Îµµ ÀÛ¿ëÇÏ´Â °Íµµ ÀÖ´Ù. |
||
| ¿µ¹® | peptide | ÇÑ±Û | ÆéƼµå |
|---|---|---|---|
| ¼³¸í | µÎ °³ÀÌ»óÀÇ ¾Æ¹Ì³ë»ê ºÐÀÚ »çÀÌ¿¡¼, ÇÑÂÊÀÇ ¾Æ¹Ì³ë±â¿Í ´Ù¸¥ ÂÊÀÇ Ä«¸£º¹½Ç±â°¡ ¹° ºÐÀÚ¸¦ ÀÒÀ¸¸é¼ ÃàÇÕÇÏ¿© ÀÌ·ç´Â ¾Æ¹Ìµå °áÇվƹ̳ë»êÀÇ ¼ö°¡ 2, 3, ¡¦ ÀÎ °æ¿ì, °¢°¢ µðÆéƼµå, Æ®¸®ÆéƼµå, ¡¦µîÀ¸·Î ºÎ¸£¸ç, ¿©·¯ °³ÀÇ ¾Æ¹Ì³ë»êÀ¸·Î ±¸¼ºµÇ´Â °ÍÀ» ¿Ã¸®°íÆéƼµå, À̺¸´Ù Å« °ÍÀ» Æú¸®ÆéƼµå¶ó°í ÇÑ´Ù. Á÷¼â»óÀÇ °ÍÀÌ ¸¹Áö¸¸, ȯ»ó ±¸Á¶¸¦ °®´Â ÆéƼµåµµ ÀÖ´Ù. ÀúºÐÀÚÀÇ ÆéƼµå´Â ¹°, »ê, ¾ËÄ®¸® µûÀ§¿¡ Àß ³ì°í ¾ËÄڿÿ¡´Â ³ìÁö ¾ÊÀ¸³ª, °íºÐÀÚÀÇ ÆéƼµå´Â ¹°¿¡ Àß ³ìÁö ¾Ê°í ´Ü¹éÁú°ú ¼ºÁúÀÌ ºñ½ÁÇÏ´Ù. ³úÇϼöüȣ¸£¸ó, ºê¶óµðŰ´Ñ µî°ú °°ÀÌ »ý¸®Àû±â´ÉÀÌ ÇöÀúÇÑ °ÍÀº »ý¸®È°¼ºÆéƼµå(bioactive peptide)¶ó°í ÇÑ´Ù. |
||
| NT, Nt | NeuroTransmitter |
|---|---|
| BNT | Boston Naming Test; brain neurotransmitter |
| C-Peptide | Connecting Peptide |
| ERP | early receptor potential; effective refractory period; elodoisin-related peptide; endoscopic retrogr... |
| VIP | vasoactive intestinal peptide; vasoinhibitory peptide; venous impedance plethysmography; ventricular... |
| C-peptide | connecting peptide |
|---|---|
| LAP | 1-latency associated peptide |
| GLP-1 | 1.Glucagon-like peptide-1 amide |
| PYY | 125)I-peptide YY |
| ANP | A type natriuretic peptide |
corticotropin-releasing factor (ºÎ½Å ÇÇÁú È£¸£¸ó À¯¸® ¿ä¼Ò, ºÎ½Å ÇÇÁú È£¸£¸ó À¯¸® ÀÎÀÚ
| peptide neurotransmitter | Small peptides used as primary or co transmitters in nerve cells for example FMRF amide, FLRFamide. (18 Nov 1997) |
|---|
| receptors, neurotransmitter | Cell surface receptors that bind signalling molecules released by neurons and convert these signals into intracellular changes influencing the behaviour of cells. Neurotransmitter is used here in its most general sense, including not only messengers that act to regulate ion channels, but also those which act on second messenger systems and those which may act at a distance from their release sites. Included are receptors for neuromodulators, neuroregulators, neuromediators, and neurohumors, whether or not located at synapses. (12 Dec 1998) |
|---|---|
| neurotransmitter | Any of a group of substances that are released on excitation from the axon terminal of a presynaptic neuron of the central or peripheral nervous system and travel across the synaptic cleft to either excite or inhibit the target cell. Among the many substances that have the properties of a neurotransmitter are acetylcholine, noradrenaline, adrenaline, dopamine, glycine, y aminobutyrate, glutamic acid, substance P, enkephalins, endorphins and serotonin. (18 Nov 1997) |
| neurotransmitter agents | Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. (12 Dec 1998) |
| neurotransmitters and neurotransmitter agents | A collective grouping for neurotransmitters and substances that act on the neurotransmitter system. (12 Dec 1998) |
| neurotransmitter system | A group of nerve cells that use the sameneurotransmitter to communicate. (22 May 1997) |
| neurotransmitter uptake inhibitors | Drugs that inhibit the transport of neurotransmitters into axon terminals or into storage vesicles within terminals. For many transmitters, uptake determines the time course of transmitter action so inhibiting uptake prolongs the activity of the transmitter. Blocking uptake may also deplete available transmitter stores. Many clinically important drugs are uptake inhibitors although the indirect reactions of the brain rather than the acute block of uptake itself is often responsible for the therapeutic effects. (12 Dec 1998) |
| alpha-aminoacyl-peptide hydrolases | <enzyme> Registry number: EC 3.4.11. (12 Dec 1998) |
| anionic neutrophil activating peptide | <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes. It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4. Acronym: IL-8 (12 Dec 1998) |
| antibiotics, peptide | Antibiotics whose structure contains one or more peptides, usually cyclic. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls. (12 Dec 1998) |
| atrial natriuretic peptide | <hormone> This cardiac hormone (28 amino acid residues) regulates salt and water balance in body fluids and blood pressure, it has potential as a medication to treat heart and kidney failure and the buildup of excess fluid in tissue. (09 Oct 1997) |
| bradykinin-potentiating peptide | <chemical> 2-l-tryptophan-3-de-l-leucine-4-de-l-proline-8-l-glutamine bradykinin potentiator b. A synthetic nonapeptide with the sequence pyr-trp-pro-arg-pro-gln-ile-pro-pro, which is identical to that of the peptide from the venom of the snake, bothrops jararaca. It acts as an inhibitor of kininase II and angiotensin I and has been proposed as an antihypertensive agent. Pharmacological action: angiotensin-converting enzyme inhibitors, antihypertensive agents. Chemical name: Bradykinin potentiator B, 2-L-tryptophan-3-de-L-leucine-4-de-L-proline-8-L-glutamine- (12 Dec 1998) |
| brain natriuretic peptide | <hormone, protein> Brain peptide that induces diuresis, related to atrial natriuretic peptide. (18 Nov 1997) |
| calcitonin gene-related peptide | <protein> A second product transcribed from the calcitonin gene. Calcitonin gene related peptide is found in a number of tissues including nervous tissue. It is a vasodilator that may participate in the cutaneous triple response. It is a neuropeptide of 37 amino acids with structural homology to salmon calcitonin. Co-localises with substance P in neurons. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator. Intracerebral administration leads to a rise in noradrenergic sympathetic outflow, a rise in blood pressure and a fall in gastric secretion. Acronym: CGRP (05 May 2002) |
| vasoactive intestinal peptide | <gastroenterology, protein> Peptide of 28 amino acids, originally isolated from porcine intestine, but later found in the central nervous system where it acts as a neuropeptide and is released by specific interneurons. May also affect behaviour of cells of the immune system. Acronym: VIP (05 Jan 1998) |
| gastrin-releasing peptide | <hormone> A regulatory peptide (27 amino acids) thought to be the mammalian equivalent of bombesin. It elicits gastrin release and regulates gastric acid secretion and motor function. It causes bronchoconstriction and vasodilation in the respiratory tract and stimulates the growth and mitogenesis of cells in culture. Once released from nerves in the antrum of the stomach, the neuropeptide stimulates release of gastrin from the g cells. Chemical name: Gastrin-releasing peptide (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|